MarketWatch: Health Round-up
Pages: 61
Publisher: Datamonitor
Date Published: July 2006
Format: PDF
Price: $400
Overview
Datamonitor’s MarketWatch Health Round-up is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the Healthcare industry. The report contains the latest news, analysis and opinion, covering all the month’s major issues and events in R&D, regulatory and licensing in the Healthcare industry.
Table of Contents
In this month’s MarketWatch…
Pharmaceutical Company Round-up
Page 3
Cancer Update
Page 4 – News Round-up
Page 7 – Opinion: Merck & Co: the marketing machine behind Gardasil
Page 8 – Opinion: Genentech/Roche: another advance for Avastin
Page 9 – Opinion: Amgen: panitumumab speeding towards approval
Page 10 – Feature Analysis: EntreMed hoping for success with Panzem/Avastin combo
Page 11 – Feature Analysis: Cell Therapeutics’ Xyotax holds much promise for few patients
Cardiovascular Update
Page 13 – News Round-up
Page 15 – Opinion: Speedel/Novartis: hypertension hype or hope?
Page 16 – Opinion: UK cardiovascular disease: statins for all?
Page 17 – Opinion: Cardiome/Astellas: FDA setback for heart drug…
Page 18 – Feature Analysis: Hypertension: excitement grows around Novartis hypertension franchise update in Big Apple…
CNS Update
Page 21 – News Round-up
Page 23 – Opinion: Elan/Biogen Idec: Tysabri on the up?
Page 24 – Opinion: Forest Laboratories: Lexapro threat looms nearer…
Page 24 – Opinion: Shire: good days ahead for Daytrana…
Page 25 – Opinion: Wyeth: UK offers Efexor relief…
Page 26 – Opinion: Endo: no pain, all gain for Lidoderm…
Page 28 – Depression sufferers still reluctant to see physician…
IDI Update
Page 30 – News Round-up
Page 33 – Opinion: Alexion: good news for new asthma approach…
Page 33 – Opinion: Merck & Co: planning to reap sweet rewards in diabetes…
Page 35 – Feature Analysis: Osteoarthritis: the silent burden…
Infectious Diseases Update
Page 37 – News Round-up
Page 39 – Opinion: MedImmune: Novartis: building its antiviral arsenal…
Page 39 – Opinion: MedImmune: Novartis: continuing its infectious diseases drive…
Page 41 – Feature Analysis: Vertex: next-generation hepatitis drugs within reach…
Company Spotlight
Page 43 – Teva Pharmaceutical Industries
Biotechnology Update
Page 49 – Biotech News Round-up
Page 52 – Opinion: AstraZeneca: CAT’s in the cradle…
Company Spotlight
Page 53 – Amgen Inc
Index
Page 60 – Pharma companies
Page 60 – Biotech companies
Page 61 – Key drugs
